Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Class C β-lactamases, also known as AmpC β-lactamases or cephalosporinases, are enzymes produced by many Gram-negative bacteria that confer resistance to a broad range of β-lactam antibiotics. These enzymes hydrolyze the amide bond in the β-lactam ring of antibiotics, rendering them ineffective. They are serine hydrolases, utilizing a serine residue to attack and hydrolyze the β-lactam ring. AmpC beta-lactamases are not inhibited by classic inhibitors such as clavulanic acid, sulbactam, or tazobactam; some newer inhibitors like avibactam can inhibit AmpC enzymes. These enzymes are a major cause of resistance to extended-spectrum cephalosporins in clinical isolates.
Hydrolyzes the beta-lactam ring of antibiotics, rendering them inactive.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Beta-lactamase Class C (AmpC).